Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Year in Review
LBCL 2022 - Year in Review
LBCL 2022 - Year in Review
Year in Review
Indirect Comparison of Liso-cel and Axi-cel for 2L Treatment of R/R LBCL Revealed Comparable Efficacy with Safety Outcomes Favoring Liso-cel
LBCL 2022 - Year in Review
Matching-adjusted indirect comparison of liso-cel to axi-cel utilizing data from the TRANSFORM and ZUMA-7 studies revealed lower odds of key CAR-T‒associated adverse events with liso-cel.
Read More ›
Year in Review
YTB323 (Rapcabtagene Autoleucel) in R/R DLBCL After ≥2 Lines of Prior Therapy
LBCL 2022 - Year in Review
Phase 1 results of YTB323 in patients with R/R DLBCL demonstrate durable efficacy with a favorable safety profile, as well as identify the recommended phase 2/3 dose.
Read More ›
Year in Review
CIBMTR Registry Analysis Evaluated the Impact of Age on Outcomes in Patients with LBCL Receiving CAR-T Therapy
LBCL 2022 - Year in Review
Data from the CIBMTR registry revealed that advanced age does not impact mortality associated with CAR-T therapy, and that CAR-T therapy is feasible in older adults.
Read More ›
Year in Review
Inflammatory Biomarker Clusters May Provide a New Means for Risk Stratification of Patients with LBCL Receiving CAR-T Therapy
LBCL 2022 - Year in Review
Two distinct inflammatory clusters were identified and found to be tightly linked to response and survival of patients with LBCL receiving CAR-T therapy, with validation utilizing an independent cohort.
Read More ›
Page 3 of 3
1
2
3
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Supported through funding by
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us